Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection

NCT04260126 is registered in ClinicalTrials.gov with PDS Biotechnology Corp. as lead sponsor.

NCT NCT04260126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04260126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection
Lead sponsor
PDS Biotechnology Corp.
Phase
Phase 2
Overall status
Completed
Start date
March 29, 2021
Completion date
May 14, 2025
Enrollment
95 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

hpv positive oropharyngeal squamous cell carcinoma, metastatic head and neck cancer, neoplasms, head and neck, recurrent head and neck cancer